Helen Dolk1, Maria Loane, Ester Garne. 1. Professor of Epidemiology and Health Services Research, University of Ulster, Co Antrim, Northern Ireland, UK. h.dolk@ulster.ac.uk
Abstract
BACKGROUND: This study determines the prevalence of Congenital Heart Defects (CHD), diagnosed prenatally or in infancy, and fetal and perinatal mortality associated with CHD in Europe. METHODS AND RESULTS: Data were extracted from the European Surveillance of Congenital Anomalies central database for 29 population-based congenital anomaly registries in 16 European countries covering 3.3 million births during the period 2000 to 2005. CHD cases (n=26 598) comprised live births, fetal deaths from 20 weeks gestation, and terminations of pregnancy for fetal anomaly (TOPFA). The average total prevalence of CHD was 8.0 per 1000 births, and live birth prevalence was 7.2 per 1000 births, varying between countries. The total prevalence of nonchromosomal CHD was 7.0 per 1000 births, of which 3.6% were perinatal deaths, 20% prenatally diagnosed, and 5.6% TOPFA. Severe nonchromosomal CHD (ie, excluding ventricular septal defects, atrial septal defects, and pulmonary valve stenosis) occurred in 2.0 per 1000 births, of which 8.1% were perinatal deaths, 40% were prenatally diagnosed, and 14% were TOPFA (TOPFA range between countries 0% to 32%). Live-born CHD associated with Down syndrome occurred in 0.5 per 1000 births, with > 4-fold variation between countries. CONCLUSION: Annually in the European Union, we estimate 36 000 children are live born with CHD and 3000 who are diagnosed with CHD die as a TOFPA, late fetal death, or early neonatal death. Investing in primary prevention and pathogenetic research is essential to reduce this burden, as well as continuing to improve cardiac services from in utero to adulthood.
BACKGROUND: This study determines the prevalence of Congenital Heart Defects (CHD), diagnosed prenatally or in infancy, and fetal and perinatal mortality associated with CHD in Europe. METHODS AND RESULTS: Data were extracted from the European Surveillance of Congenital Anomalies central database for 29 population-based congenital anomaly registries in 16 European countries covering 3.3 million births during the period 2000 to 2005. CHD cases (n=26 598) comprised live births, fetal deaths from 20 weeks gestation, and terminations of pregnancy for fetal anomaly (TOPFA). The average total prevalence of CHD was 8.0 per 1000 births, and live birth prevalence was 7.2 per 1000 births, varying between countries. The total prevalence of nonchromosomal CHD was 7.0 per 1000 births, of which 3.6% were perinatal deaths, 20% prenatally diagnosed, and 5.6% TOPFA. Severe nonchromosomal CHD (ie, excluding ventricular septal defects, atrial septal defects, and pulmonary valve stenosis) occurred in 2.0 per 1000 births, of which 8.1% were perinatal deaths, 40% were prenatally diagnosed, and 14% were TOPFA (TOPFA range between countries 0% to 32%). Live-born CHD associated with Down syndrome occurred in 0.5 per 1000 births, with > 4-fold variation between countries. CONCLUSION: Annually in the European Union, we estimate 36 000 children are live born with CHD and 3000 who are diagnosed with CHD die as a TOFPA, late fetal death, or early neonatal death. Investing in primary prevention and pathogenetic research is essential to reduce this burden, as well as continuing to improve cardiac services from in utero to adulthood.
Authors: Anthony Wemakor; Karen Casson; Ester Garne; Marian Bakker; Marie-Claude Addor; Larraitz Arriola; Miriam Gatt; Babak Khoshnood; Kari Klungsoyr; Vera Nelen; Mary O'Mahoney; Anna Pierini; Anke Rissmann; David Tucker; Breidge Boyle; Lolkje de Jong-van den Berg; Helen Dolk Journal: Eur J Epidemiol Date: 2015-07-07 Impact factor: 8.082
Authors: Mitchel R Stacy; Cameron A Best; Mark W Maxfield; Maolin Qiu; Yuji Naito; Hirotsugu Kurobe; Nathan Mahler; Kevin A Rocco; Albert J Sinusas; Toshiharu Shinoka; Smita Sampath; Christopher K Breuer Journal: Tissue Eng Part C Methods Date: 2018-07-31 Impact factor: 3.056
Authors: Matthew E Oster; Kyung A Lee; Margaret A Honein; Tiffany Riehle-Colarusso; Mikyong Shin; Adolfo Correa Journal: Pediatrics Date: 2013-04-22 Impact factor: 7.124
Authors: Angela E Lin; Sergey Krikov; Tiffany Riehle-Colarusso; Jaime L Frías; John Belmont; Marlene Anderka; Tal Geva; Kelly D Getz; Lorenzo D Botto Journal: Am J Med Genet A Date: 2014-08-06 Impact factor: 2.802
Authors: Hassan Ashraf; Lagnajeet Pradhan; Eileen I Chang; Ryota Terada; Nicole J Ryan; Laura E Briggs; Rajib Chowdhury; Miguel A Zárate; Yukiko Sugi; Hyun-Joo Nam; D Woodrow Benson; Robert H Anderson; Hideko Kasahara Journal: Circ Cardiovasc Genet Date: 2014-07-15
Authors: Najim Lahrouchi; Alex V Postma; Christian M Salazar; Daniel M De Laughter; Fleur Tjong; Lenka Piherová; Forrest Z Bowling; Dominic Zimmerman; Elisabeth M Lodder; Asaf Ta-Shma; Zeev Perles; Leander Beekman; Aho Ilgun; Quinn Gunst; Mariam Hababa; Doris Škorić-Milosavljević; Viktor Stránecký; Viktor Tomek; Peter de Knijff; Rick de Leeuw; Jamille Y Robinson; Sabrina C Burn; Hiba Mustafa; Matthew Ambrose; Timothy Moss; Jennifer Jacober; Dmitriy M Niyazov; Barry Wolf; Katherine H Kim; Sara Cherny; Andreas Rousounides; Aphrodite Aristidou-Kallika; George Tanteles; Bruel Ange-Line; Anne-Sophie Denommé-Pichon; Christine Francannet; Damara Ortiz; Monique C Haak; Arend D.J. Ten Harkel; Gwendolyn Tr Manten; Annemiek C Dutman; Katelijne Bouman; Monia Magliozzi; Francesca Clementina Radio; Gijs We Santen; Johanna C Herkert; H Alex Brown; Orly Elpeleg; Maurice Jb van den Hoff; Barbara Mulder; Michael V Airola; Stanislav Kmoch; Joey V Barnett; Sally-Ann Clur; Michael A Frohman; Connie R Bezzina Journal: J Clin Invest Date: 2021-03-01 Impact factor: 14.808